Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D). Additionally, the company is advancing Dorzagliatin through Phase I clinical trials when combined with Metformin, Sitagliptin, and Empagliflozin, also for T2D therapy. Dorzagliatin's potential extends to other applications, including combinations with Pioglitazone for NASH, with GLP-1 for Alzheimer's disease, and for the management of both late-stage Type 2 and Type 1 Diabetes. Furthermore, Hua Medicine is also progressing mGLUR5, an investigational treatment targeting levodopa-induced dyskinesia in Parkinson's disease. Established in 2011, the company's operations are headquartered in Beijing, China.
—
Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D). Additionally, the company is advancing Dorzagliatin through Phase I clinical trials when combined with Metformin, Sitagliptin, and Empagliflozin, also for T2D therapy. Dorzagliatin's potential extends to other applications, including combinations with Pioglitazone for NASH, with GLP-1 for Alzheimer's disease, and for the management of both late-stage Type 2 and Type 1 Diabetes. Furthermore, Hua Medicine is also progressing mGLUR5, an investigational treatment targeting levodopa-induced dyskinesia in Parkinson's disease. Established in 2011, the company's operations are headquartered in Beijing, China.
—
Daily adjusted close
Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D). Additionally, the company is advancing Dorzagliatin through Phase I clinical trials when combined with Metformin, Sitagliptin, and Empagliflozin, also for T2D therapy. Dorzagliatin's potential extends to other applications, including combinations with Pioglitazone for NASH, with GLP-1 for Alzheimer's disease, and for the management of both late-stage Type 2 and Type 1 Diabetes. Furthermore, Hua Medicine is also progressing mGLUR5, an investigational treatment targeting levodopa-induced dyskinesia in Parkinson's disease. Established in 2011, the company's operations are headquartered in Beijing, China.